Kimberly-Clark Sees Rogaine Sales Jump 30%

Kimberly-Clark's third-quarter net sales slipped 0.4% as its newly acquired Rogaine brand grew strongly, according to the company's earnings report.

Updated on Nov. 5, 2026 in Consumer Goods

Kimberly-Clark Sees Rogaine Sales Jump 30%

Live Poll

Have you or someone you know changed hair-care habits while taking weight loss drugs?

Kimberly-Clark reported third-quarter net sales of $4.1 billion, down 0.4% from a year earlier, while Rogaine sales rose 30% year-to-date. The company completed its Kenvue acquisition earlier in the week, bringing Rogaine into its portfolio.

Why it matters

Kimberly-Clark CEO Mike Hsu said the Rogaine increase may be driven by adoption of GLP-1 weight loss drugs, some users of which experience hair loss. The results show how the Kenvue deal is reshaping the company's consumer lineup in the United States.

Kimberly-Clark's third-quarter net sales reached $4.1 billion, down 0.4% from a year earlier, while Rogaine sales climbed 30% year-to-date. The company has not broken out how much of that Rogaine growth is tied to GLP-1 drug users.

The players

Kimberly-Clark

A major American consumer products company known for brands such as Kleenex and Huggies, which expanded its personal care lineup through the Kenvue acquisition.

Mike Hsu

The chief executive of Kimberly-Clark who linked the Rogaine sales increase to growing adoption of GLP-1 weight loss drugs.

The details

Rogaine came to Kimberly-Clark through its purchase of Kenvue, which closed earlier this week. The Kenvue deal is valued at roughly $36 billion, including $6.7 billion in cash, with JPMorgan Chase supplying $7.7 billion in bridge financing.

October 2026: Kimberly-Clark weighed a bond offering to help finance the Kenvue takeover.
Early in the week of November 5, 2026: Kimberly-Clark completed the Kenvue acquisition.
Thursday, November 5, 2026: Kimberly-Clark discussed Rogaine sales on its earnings call.

Market Landscape

The Rogaine surge illustrates how GLP-1 weight loss drugs, some of which cause hair loss, are creating new demand in adjacent consumer categories. Procter & Gamble has responded by introducing a version of its Pantene brand aimed at hair loss, signaling a competitive push in the same space.

Shoppers who use Rogaine may see the brand's continued growth reflected in product availability under Kimberly-Clark's ownership. The Kenvue portfolio, which includes Tylenol, Band-Aid, Benadryl, Listerine and Neutrogena lotion, now sits under the same corporate umbrella.

The takeaway

Consumers tracking health-related product trends should watch how GLP-1 drug side effects create demand in adjacent categories like hair care. Companies are responding quickly, as the Pantene launch shows.